Furthermore, squamous and sarcomatoid differentiation, tumor grade, and histological subtypes were significantly enriched in the responder cohort (all p < 0.001), indicating that tumors with more aggressive or immunogenic characteristics may be more sensitive to adjuvant therapy.Notably, HER2 overexpression (score 2 or 3) was more prevalent in responders than in non-responders (25% vs. 12%, p < 0.001), highlighting its potential role as a predictive biomarker for treatment response. This evidence concerns the gene ERBB2 and neoplasm.